Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 61

Sort by

Sort Order Select

Journal Articles

Radiation-Based Approaches As an Alternative to Stem Cell Transplant for Relapsed/Refractory Classical Hodgkin Lymphoma: A Multicenter Retrospective Analysis

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-142089

Published: 2020

Journal Articles

Anti-CD19 CAR-T for Treatment of Double Expressor and Double Hit Large B-Cell Lymphomas: A Single Institution Real-World Analysis

Elise A. Chong, MD, Emeline R. Chong, Daniel J. Landsburg, MD, James N. Gerson, MD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, Stefan K. Barta, MDMRCP,MS, Alfred L. Garfall, MD, Elizabeth Weber, BSN, RN, Marco Ruella, MD, Noelle V. Frey, MD, David L. Porter, MD, Stephen J. Schuster, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-143348

Published: 2020

Journal Articles

Everolimus Plus Itacitinib in Relapsed/Refractory Classical Hodgkin Lymphoma: Results of a Phase I/II Investigator Initiated Trial (EVITA Study)

Jakub Svoboda, MD, Stefan K. Barta, MDMRCP,MS, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, Wei-Ting Hwang, PhD, Grace Delp, Brittany Amundsen, Hatcher J. Ballard, BS, James N. Gerson, MD, Elise A. Chong, MD, Mitchell E. Hughes, PharmD, Steven A. Emanuel, Marco Ruella, MD, Stephen J. Schuster, MD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-140507

Published: 2020

Journal Articles

Concurrent Use of Novel Agents and Radiation Is Tolerated in Lymphoma Patients

Carrie I Ho, MD, Hatcher J. Ballard, BS, W. Tris Arscott, MD, Mitchell E. Hughes, PharmD, Abigail Doucette, MPH, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, James N. Gerson, MD, Amit Maity, MD PhD, Stephen J. Schuster, MD, Stefan K. Barta, MD MRCP, MS, John Plastaras, MD, Jakub Svoboda, MD

Blood (2019) 134 (Supplement_1): 2905.

https://doi.org/10.1182/blood-2019-124195

Published: 2019

Journal Articles

Outcomes of Patients with Refractory Peripheral T-Cell Lymphoma, Angioimmunoblastic and Other Nodal Lymphomas of T Follicular Helper-Cell Origin (OPerA)

Joanna M Rhodes, MD, Suchitra Sundaram, MD, Adam Zayac, MD, Adam J Olszewski, MD, Paolo Caimi, MD, Zachary Braunstein, MD, Jonathan E Brammer, MD, Waqas Jehangir, MD, Elvira Umyarova, MD, Sheenu Sheela, MD, Nilanjan Ghosh, MD PhD, Sunita Dwivedy Nasta, MD, Stefan K. Barta, MD MRCP, MS

Blood (2019) 134 (Supplement_1): 2854.

https://doi.org/10.1182/blood-2019-124447

Published: 2019

Journal Articles

Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Multicenter Retrospective Analysis

Jakub Svoboda, MD, Hatcher J. Ballard, BS, Steven M. Bair, MD, Rahul Banerjee, MD, Charalambos Andreadis, MD, Tatyana A. Feldman, MD, Elizabeth L. McCarthy, MSN, RN, Niloufer Khan, MD, Alison J. Moskowitz, MD, Victor M. Orellana-Noia, MD, Craig A. Portell, MD, Sarah J. Nagle, MD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, Elise A. Chong, MD, Stephen J Schuster, MD

Blood (2019) 134 (Supplement_1): 2855.

https://doi.org/10.1182/blood-2019-123741

Published: 2019

Journal Articles

Outcomes in Aggressive B-Cell Non-Hodgkin Lymphomas with Anti-CD19 CAR T-Cell (CTL019) Products Not Meeting Commercial Release Specifications

Elise A. Chong, MD, James N. Gerson, MD, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, Jakub Svoboda, MD, David L. Porter, MD, Karen Dengel, BSN, RN, Don L. Siegel, MD PhD, Joan Gilmore, BS, Stefan K. Barta, MD MRCP, MS, Bruce L Levine, PhD, Carl H June, MD, Stephen J. Schuster, MD

Blood (2019) 134 (Supplement_1): 594.

https://doi.org/10.1182/blood-2019-131078

Published: 2019

Journal Articles

Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV + PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated with Tabelecleucel on an Expanded Access Program

Susan Prockop, MD, Ran Reshef, MDMSc, Donald E. Tsai, MD PhD, Nancy Bunin, MD, Rolla Abu-Arja, MD, Kris Michael Mahadeo, MD, Wen-Kai Weng, MD PhD, Koen Van Besien, MD PhD, David Loeb, MD PhD, Sunita Dwivedy Nasta, MD, Eneida R. Nemecek, MDMBA,MSc, Minoti Hiremath, MBBS, PhD, Susan Yue, MD, Yan Sun, PhD, Willis Navarro, MD, Sarah Nikiforow, MD PhD

Blood (2019) 134 (Supplement_1): 4071.

https://doi.org/10.1182/blood-2019-124904

Published: 2019

Journal Articles

A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy

Sunita Dwivedy Nasta, MD, Mitchell E. Hughes, PharmD, Esin C. Namoglu, B.S., Daniel J. Landsburg, MD, Elise A. Chong, MD, Stefan K. Barta, MD MRCP, MS, Noelle V. Frey, MD, James N. Gerson, MD, Amit Maity, MD PhD, John Plastaras, MD, David L. Porter, MD, Marco Ruella, MD, Jakub Svoboda, MD, Hatcher J. Ballard, BS, Stephen J. Schuster, MD

Blood (2019) 134 (Supplement_1): 4108.

https://doi.org/10.1182/blood-2019-131399

Published: 2019

Journal Articles

Clinical Outcomes of Obinutuzumab Therapy across Non-Hodgkin Lymphoma Subtypes

Mitchell E. Hughes, PharmD, Esin C. Namoglu, B.S., Connie Suen, PharmD, Stephen J Schuster, MD, Jakub Svoboda, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, James N. Gerson, MD, Kyle Robinson, MD, Elise A. Chong, MD, Joanna M Rhodes, MD, Emily C. Ayers, MD, Alison W. Loren, MD MSCE, Edward A. Stadtmauer, MD FACP, Sunita Dwivedy Nasta, MD

Blood (2019) 134 (Supplement_1): 5247.

https://doi.org/10.1182/blood-2019-128148

Published: 2019

Journal Articles

Outcomes and Toxicities of Ibrutinib in Marginal Zone Lymphoma: A Retrospective Cohort Study at a Single Institution

David M. Weiner, BA, Nathaniel D. Robinson, MD, Steven M. Bair, MD, Hatcher J. Ballard, BS, Mitchell E. Hughes, PharmD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, Elise A. Chong, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD

Blood (2019) 134 (Supplement_1): 5250.

https://doi.org/10.1182/blood-2019-128556

Published: 2019

Journal Articles

Clinical Outcomes of Non-Hodgkin Lymphoma Patients on Acalabrutinib Including Off-Label Utilization

Esin C. Namoglu, B.S., Mitchell E. Hughes, PharmD, Daniel J. Landsburg, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD, Elise A. Chong, MD, James N. Gerson, MD, Stefan K. Barta, MD MRCP, MS, Sunita Dwivedy Nasta, MD

Blood (2019) 134 (Supplement_1): 5261.

https://doi.org/10.1182/blood-2019-130039

Published: 2019

Journal Articles

Hospitalization Patterns with Commercial CAR T-Cell Therapy: A Single Institution Experience

Sunita Dwivedy Nasta, MD, Esin C. Namoglu, B.S., Mitchell E. Hughes, PharmD, Elise A. Chong, MD, Jakub Svoboda, MD, Hatcher J. Ballard, BS, Daniel J. Landsburg, MD, Meredith I LaRose, MD, Stefan K. Barta, MD MRCP, MS, James N. Gerson, MD, Marco Ruella, MD, Noelle V. Frey, MD, Stephen J. Schuster, MD, David L. Porter, MD

Blood (2019) 134 (Supplement_1): 3240.

https://doi.org/10.1182/blood-2019-130650

Published: 2019

Journal Articles

Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas

Jakub Svoboda, MD, Hatcher J. Ballard, BS, Elise A. Chong, MD, Meredith I LaRose, MD, Steven M. Bair, MD, Esin C. Namoglu, B.S., Mitchell E. Hughes, PharmD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, James N. Gerson, MD, Elizabeth Weber, BSN, RN, Chase Walling, BS, Marco Ruella, MD, Noelle V. Frey, MD, David L. Porter, MD, Stephen J. Schuster, MD

Blood (2019) 134 (Supplement_1): 1606.

https://doi.org/10.1182/blood-2019-131482

Published: 2019

Journal Articles

Outcomes for Double Hit Lymphoma Patients Identified Via Routine Vs Selective Testing for MYC Rearrangement

Zachary AK Frosch, MD, Sunita Dwivedy Nasta, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD, Stefan K. Barta, MD MRCP, MS, James N. Gerson, MD, Elise A. Chong, MD, Emily C. Ayers, MD, Joanna M Rhodes, MD, Alexa Koike, Jennifer J.D. Morrissette, PhD, Daniel J. Landsburg, MD

Blood (2019) 134 (Supplement_1): 1607.

https://doi.org/10.1182/blood-2019-125944

Published: 2019

Journal Articles

Primary Mediastinal B-Cell Lymphoma: Evaluation of Clinicopathologic Diagnosis Compared to Gene Expression Based Diagnosis in a Clinical Trial with CD30+ B-Cell Lymphomas

Jakub Svoboda, MD, Steven M. Bair, MD, Christian Steidl, MD, Marco Ruella, MD, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, Stefan Klaus Barta, MD MRCP, MS, M. Reza Nejati, MD, James Nathan Gerson, MD, Lauren Elizabeth Strelec, BA, Matthew R. Youngman, BS, Elise A. Chong, MD, Olga Kutovaya, PhD, Stacy Hung, Agata M. Bogusz, MD PhD, Megan S. Lim, MD, PhD, Stephen J. Schuster, MD

Blood (2018) 132 (Supplement 1): 2959.

https://doi.org/10.1182/blood-2018-99-115024

Published: 2018

Journal Articles

Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type Peripheral T-Cell Lymphoma

Andrei R. Shustov, MD, Steven M. Horwitz, MD, Jasmine Zain, MD, Manish R Patel, MD, Sanjay Goel, MD, Lubomir Sokol, MD PhD, Funda Meric-Bernstam, MD, Geoffrey Shapiro, MD PhD, Sunita Dwivedy Nasta, MD, Murali Janakiram, MD MS, David M Weinstock, MD, Ronald Korn, MD PhD, Marie Payton, MBA, D. Allen Annis, PhD, Dawn Pinchasik, MD, Manuel Aivado, MD PhD, Amitkumar Mehta, MD

Blood (2018) 132 (Supplement 1): 1623.

https://doi.org/10.1182/blood-2018-99-116780

Published: 2018

Journal Articles

Outcomes of Patients with Relapsed/Refractory Double Expressor B Cell Lymphoma As Defined By Multicenter Pathology Review Treated with Ibrutinib Monotherapy

Daniel J. Landsburg, MD, Mitchell E. Hughes, PharmD, Alexa Koike, David A. Bond, MD, Kami J. Maddocks, MD, Ling Guo, MD, Allison M. Winter, MD, Brian T. Hill, MD PhD, Sarah L. Ondrejka, DO, Eric D. Hsi, MD, Sunita Dwivedy Nasta, MD, Jakub Svoboda, MD, Stephen J. Schuster, MD, Agata M. Bogusz, MDPhD

Blood (2018) 132 (Supplement 1): 455.

https://doi.org/10.1182/blood-2018-99-117514

Published: 2018

Journal Articles

Characteristics and Outcomes of Ibrutinib-Associated Musculoskeletal Toxicities in CLL Patients

Joanna Rhodes, MD, Anthony R. Mato, MD MSCE, Nicole Winchell, Kaitlin Kennard, RN, BSN, James Nathan Gerson, MD, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, Jakub Svoboda, MD, Stephen J. Schuster, MD

Blood (2018) 132 (Supplement 1): 4418.

https://doi.org/10.1182/blood-2018-99-115377

Published: 2018

Journal Articles

Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Elise A. Chong, MD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Nicole Winchell, Ellen Napier, NP, Anthony R. Mato, MD MSCE, J. Joseph Melenhorst, PhD, Marco Ruella, MD, Simon F Lacey, PhD BS, Carl H June, MD, Stephen J. Schuster, MD

Blood (2018) 132 (Supplement 1): 4198.

https://doi.org/10.1182/blood-2018-99-119502

Published: 2018

NARROW

Radiation-Based Approaches As an Alternative to Stem Cell Transplant for Relapsed/Refractory Classical Hodgkin Lymphoma: A Multicenter Retrospective Analysis

Anti-CD19 CAR-T for Treatment of Double Expressor and Double Hit Large B-Cell Lymphomas: A Single Institution Real-World Analysis

Everolimus Plus Itacitinib in Relapsed/Refractory Classical Hodgkin Lymphoma: Results of a Phase I/II Investigator Initiated Trial (EVITA Study)

Concurrent Use of Novel Agents and Radiation Is Tolerated in Lymphoma Patients

Outcomes of Patients with Refractory Peripheral T-Cell Lymphoma, Angioimmunoblastic and Other Nodal Lymphomas of T Follicular Helper-Cell Origin (OPerA)

Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Multicenter Retrospective Analysis

Outcomes in Aggressive B-Cell Non-Hodgkin Lymphomas with Anti-CD19 CAR T-Cell (CTL019) Products Not Meeting Commercial Release Specifications

Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV + PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated with Tabelecleucel on an Expanded Access Program

A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy

Clinical Outcomes of Obinutuzumab Therapy across Non-Hodgkin Lymphoma Subtypes

Outcomes and Toxicities of Ibrutinib in Marginal Zone Lymphoma: A Retrospective Cohort Study at a Single Institution

Clinical Outcomes of Non-Hodgkin Lymphoma Patients on Acalabrutinib Including Off-Label Utilization

Hospitalization Patterns with Commercial CAR T-Cell Therapy: A Single Institution Experience

Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas

Outcomes for Double Hit Lymphoma Patients Identified Via Routine Vs Selective Testing for MYC Rearrangement

Primary Mediastinal B-Cell Lymphoma: Evaluation of Clinicopathologic Diagnosis Compared to Gene Expression Based Diagnosis in a Clinical Trial with CD30+ B-Cell Lymphomas

Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type Peripheral T-Cell Lymphoma

Outcomes of Patients with Relapsed/Refractory Double Expressor B Cell Lymphoma As Defined By Multicenter Pathology Review Treated with Ibrutinib Monotherapy

Characteristics and Outcomes of Ibrutinib-Associated Musculoskeletal Toxicities in CLL Patients

Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only